Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers (eBook, PDF)

Multidisciplinary Management

• Format: PDF

Produktbeschreibung

This book aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer. The advent of immunotherapy has revolutionized treatments of genitourinary malignancy and evolved strategies for multidisciplinary management. This book explains neoadjuvant checkpoint inhibitors in localized genitourinary cancers, providing insights into the mechanisms of response and development of resistance of cancer cells to immunotherapy. It debates optimal trial design of preoperative checkpoint inhibitors in GU tumors, including optimal endpoints and the role of pathologic response as a surrogate endpoint of survival. It also illuminates clinical management of patients with organ-confined GU tumors, such as side effect management and perioperative safety, before providing an overview of biomarker use for patient selection across the early-stage GU malignancies. Lastly, the book provides the reader with the most up-to-date data emerging from clinical trials involving immunotherapy in early-stage GU malignancies.
Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management provides a comprehensive review of the field, serving as a valuable resource for urologists, medical oncologists, pathologists, fellows in urologic oncology, upper-level residents training in urology and medical oncology, as well as pharmacists interested in RCC clinicians.

Produktdetails

• Verlag: Springer International Publishing
• Erscheinungstermin: 3. Januar 2022
• Englisch
• ISBN-13: 9783030805463
• Artikelnr.: 63248726

Autorenporträt

Andrea Necchi
Associate Professor, Vita-Salute San Raffaele University Head of Genitourinary Medical Oncology IRCCS San Raffaele Hospital and Scientific Institute Via Olgettina 60, 20132 Milan, Italy
Philippe E. Spiess Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant Chief of Surgical Services Moffitt Cancer Center Professor, Department of Urology University of South Florida Tampa, Florida USA

Inhaltsangabe

Introduction.- State-of-the art and ongoing developments.- Clinical cases debate: neoadjuvant checkpoint inhibition vs standard chemotherapy.- Slideshow of tumor samples before and after checkpoint inhibition.- Ongoing trials and clinical trials endpoints debate: the role of pathological response as a surrogate of survival endpoints.- State-of-the-art and future role of molecular biomarkers for patient selection.- Background of immunotherapy trials in prostate cancer.- Clinical case debate: immunotherapy vs alternative therapies in the neoadjuvant and adjuvant setting of localized, high-risk prostate cancer.- Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy.- Clinical cases debate: Neoadjuvant vs adjuvant immunotherapy in localized RCC.- Benchmark of surgical safety results.- What the scientific data tell us about predictive biomarkers of immunotherapy efficacy across the GU malignancies.- Clinical cases debate: biomarker-driven patient selection vs unselective perioperative strategies.

---

Introduction.- State-of-the art and ongoing developments.- Clinical cases debate: neoadjuvant checkpoint inhibition vs standard chemotherapy.- Slideshow of tumor samples before and after checkpoint inhibition.- Ongoing trials and clinical trials endpoints debate: the role of pathological response as a surrogate of survival endpoints.- State-of-the-art and future role of molecular biomarkers for patient selection.- Background of immunotherapy trials in prostate cancer.- Clinical case debate: immunotherapy vs alternative therapies in the neoadjuvant and adjuvant setting of localized, high-risk prostate cancer.- Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy.- Clinical cases debate: Neoadjuvant vs adjuvant immunotherapy in localized RCC.- Benchmark of surgical safety results.- What the scientific data tell us about predictive biomarkers of immunotherapy efficacy across the GU malignancies.- Clinical cases debate: biomarker-driven patient selection vs unselective perioperative strategies.